Login to Your Account



La Jolla phase III top-line data in CRH pleasing to Street

By Randy Osborne
Staff Writer

Monday, February 27, 2017

Maybe some were less than surprised by the gist of phase III results tallied by La Jolla Pharmaceutical Co. in the ATHOS-3 study with LJPC-501 in patients with CRH associated with distributive shock, but the data hinted at an even brighter picture and Wall Street rewarded the firm handsomely.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription